Increased accumulation of doxorubicin and doxorubicinol in cardiac tissue of mice lacking mdr1a P-glycoprotein (original) (raw)

References

• Bartlett, N. L., Lum, B. L., Fisher, G. A., Brophy, N. A., Ehsan, M. N., Halsey, J. & Sikic, B. I. (1994). Phase I trial of doxorubicin with cyclosporine as a modulator of multidrug resistance. J Clin Oncol 12: 835–842.
  Article CAS Google Scholar
• Bellamy, W. T., Peng, Y. M., Odeleye, A., Ellsworth, L., Xu, M. J., Grogan, T. M. & Weinstein, R. S. (1995). Cardiotoxicity in the SCID mouse following administration of doxorubicin and cyclosporin A. Anti-Cancer Drugs 6: 736–743.
  Article CAS Google Scholar
• Colombo, T., Zucchetti, M. & D'Incalci, M. (1994). Cyclosporin A markedly changes the distribution of doxorubicin in mice and rats. J Pharmacol Exp Ther 269: 22–27.
  CAS PubMed Google Scholar
• Cordon-Cardo, C., O'Brien, J. P., Casals, D., Rittman-Grauer, L., Biedler, J. L., Melamed, M. R. & Bertino, J. R. (1989). Multidrug-resistance gene (P-glycoprotein) is expressed by endothelial cells at blood–brain barrier sites. Proc Natl Acad Sci USA 86: 695–698.
  Article CAS Google Scholar
• Croop, J. M., Raymond, M., Haber, D., Devault, A., Arceci, R. J., Gros, P. & Housman, D. E. (1989). The three mouse multidrug resistance (mdr) genes are expressed in a tissue-specific manner in normal mouse tissues. Mol Cell Biol 9: 1346–1350.
  Article CAS Google Scholar
• Dantzig, A. H., Shepard, R. L., Cao, J., Law, K. L., Ehlhardt, W. J., Baughman, T. M., Bumol, T. F. & Starling, J. J. (1996). Reversal of P-glycoprotein-mediated multidrug resistance by a potent cyclopropyldibenzosuberane modulator, LY335979. Cancer Res 56: 4171–4179.
  CAS PubMed Google Scholar
• De Jong, J., Schoofs, P. R., Snabilié, A. M., Bast, A. & van der Vijgh, W. J. F. (1993). The role of biotransformation in anthracycline-induced cardiotoxicity in mice. J Pharmacol Exp Ther 266: 1312–1320.
  CAS PubMed Google Scholar
• Endicott, J. A. & Ling, V. (1989). The biochemistry of P-glycoprotein-mediated multidrug resistance. Annu Rev Biochem 58: 137–171.
  Article CAS Google Scholar
• Erlichman, C., Moore, M., Thiessen, J. J., Kerr, I. G., Walker, S., Goodman, P., Bjarnason, G., DeAngelis, C. & Bunting, P. (1993). Phase I pharmacokinetic study of cyclosporin A combined with doxorubicin. Cancer Res 53: 4837–4842.
  CAS PubMed Google Scholar
• Giaccone, G., Linn, S. C., Welink, J., Catimel, G., Stieltjes, H., van der Vijgh, W. J. F., Eeltink, C., Vermorken, J. B. & Pinedo, H. M. (1997). A dose-finding and pharmacokinetic study of reversal of multidrug resistance with SDZ PSC 833 in combination with doxorubicin in patients with solid tumors. Clin Cancer Res 3: 2005–2015.
  CAS PubMed Google Scholar
• Gonzalez, O., Colombo, T., De Fusco, M., Imperatori, L., Zucchetti, M. & D'Incalci, M. (1995). Changes in doxorubicin distribution and toxicity in mice pretreated with the cyclosporin analogue SDZ PSC 833. Cancer Chemother Pharmacol 36: 335–340.
  Article CAS Google Scholar
• Hyafil, F., Vergely, C., du Vignaud, P. & Grand-Perret, T. (1993). In vitro and in vivo reversal of multidrug resistance by GF120918, an acridonecarboxamide derivative. Cancer Res 53: 4595–4602.
  CAS PubMed Google Scholar
• Mayer, U., Wagenaar, E., Beijnen, J. H., Smit, J. W., Meijer, D. K. F., van Asperen, J., Borst, P. & Schinkel, A. H. (1996). Substantial excretion of digoxin via the intestinal mucosa and prevention of long-term digoxin accumulation in the brain by mdr1a P-glycoprotein. Br J Pharmacol 119: 1038–1044.
  Article CAS Google Scholar
• Mayer, U., Wagenaar, E., Dorobek, B., Beijnen, J. H., Borst, P. & Schinkel, A. H. (1997). Full blockade of intestinal P-glycoprotein and extensive inhibition of blood–brain barrier P-glycoprotein by oral treatment of mice with PSC833. J Clin Invest 100: 2430–2436.
  Article CAS Google Scholar
• Mross, K., Maessen, P., van der Vijgh, W. J. F., Gall, H., Boven, E. & Pinedo, H. M. (1988). Pharmacokinetics and metabolism of epidoxorubicin and doxorubicin in humans. J Clin Oncol 6: 517–526.
  Article CAS Google Scholar
• Olson, R. D., Mushlin, P. S., Brenner, D. E., Fleischer, S., Cusack, B. J., Chang, B. K. & Boucek, R. J. (1988). Doxorubicin cardiotoxicity may be caused by its metabolite, doxorubicinol. Proc Natl Acad Sci USA 85: 3585–3589.
  Article CAS Google Scholar
• Schinkel, A. H., Smit, J. J. M., van Tellingen, O., Beijnen, J. H., Wagenaar, E., van Deemter, L., Mol, CAAM, van der Valk, M. A., Robanus-Maandag, E. C., te Riele, H. P. J., Berns, A. J. M. & Borst, P. (1994). Disruption of the mouse_mdr1a_P-glycoprotein gene leads to a deficiency in the blood–brain barrier and to increased sensitivity to drugs. Cell 77: 491–502.
  Article CAS Google Scholar
• Schinkel, A. H., Wagenaar, E., van Deemter, L., Mol, CAAM & Borst, P. (1995). Absence of the mdr1a P-glycoprotein in mice affects tissue distribution and pharmacokinetics of dexamethasone, digoxin, and cyclosporin A. J Clin Invest 96: 1698–1705.
  Article CAS Google Scholar
• Schinkel, A. H., Wagenaar, E., Mol, CAAM & van Deemter, L. (1996). P-glycoprotein in blood–brain barrier of mice influences the brain penetration and pharmacological activity of many drugs. J Clin Invest 97: 2517–2524.
  Article CAS Google Scholar
• Schinkel, A. H., Mayer, U., Wagenaar, E., Mol, CAAM, van Deemter, L., Smit, J. J. M., van der Valk, M. A., Voordouw, A. C., Spits, H., van Tellingen, O., Zijlmans, JMJM, Fibbe, W. E. & Borst, P. (1997). Normal viability and altered pharmacokinetics in mice lacking mdr1-type (drug-transporting) P-glycoproteins. Proc Natl Acad Sci USA 94: 4028–4033.
  Article CAS Google Scholar
• Sparreboom, A., van Asperen, J., Mayer, U., Schinkel, A. H., Smit, J. W., Meijer, D. K. F., Borst, P., Nooijen, W. J., Beijnen, J. H. & van Tellingen, O. (1997). Limited oral bioavailability and active epithelial excretion of paclitaxel (Taxol) caused by P-glycoprotein in the intestine. Proc Natl Acad Sci USA 94: 2031–2035.
  Article CAS Google Scholar
• Tang-Wai, D. F., Kajiji, S., DiCapua, F., de Graaf, D., Roninson, I. B. & Gros, P. (1995). Human (MDR1) and mouse (mdr1, mdr3) P-glycoproteins can be distinguished by their respective drug resistance profiles and sensitivity to modulators. Biochemistry 34: 32–39.
  Article CAS Google Scholar
• Thiebaut, F., Tsuruo, T., Hamada, H., Gottesman, M. M., Pastan, I. & Willingham, M. C. (1987). Cellular localization of the multidrug resistance gene product P-glycoprotein in normal human tissues. Proc Natl Acad Sci USA 84: 7735–7738.
  Article CAS Google Scholar
• Tsuruo, T., Iida, H., Tsukagoshi, S. & Sakurai, Y. (1981). Overcoming of vincristine resistance in P388 leukemia in vivo and in vitro through enhanced cytotoxicity of vincristine and vinblastine by verapamil. Cancer Res 41: 1967–1972.
  CAS PubMed Google Scholar
• Van Asperen, J., Schinkel, A. H., Beijnen, J. H., Nooijen, W. J., Borst, P. & van Tellingen, O. (1996). Altered pharmacokinetics of vinblastine in mdr1a P-glycoprotein-deficient mice. J Natl Cancer Inst 88: 994–999.
  Article CAS Google Scholar
• Van Asperen, J., van Tellingen, O. & Beijnen, J. H. (1998). Determination of doxorubicin and metabolites in murine specimens by high-performance liquid chromatography. J Chromatogr B 712: 129–143.
  Article CAS Google Scholar
• Wacher, V. J., Wu, C-Y & Benet, L. Z. (1995). Overlapping substrate specificities and tissue distribution of cytochrome P450 3A and P-glycoprotein: implications for drug delivery and activity in cancer chemotherapy. Mol Carcinogen 13: 129–134.
  Article CAS Google Scholar
• Webster, L. K., Cosson, E. J., Stokes, K. H. & Millward, M. J. (1996). Effect of the paclitaxel vehicle, Cremophor EL, on the pharmacokinetics of doxorubicin and doxorubicinol in mice. Br J Cancer 73: 522–524.
  Article CAS Google Scholar

Download references